Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Genotype Prostate Cancer Samples for Cancer Research UK in $7M Deal

NEW YORK, April 11 (GenomeWeb News) - Illumina will genotype prostate cancer samples for Cancer Research UK, the company said today.


Under the agreement, valued at almost $7 million, Illumina will provide genotyping services to researchers at Cancer Research UK, a non-profit research organization. Initially, Ilumina will conduct whole-genome genotyping for at least 4,000 prostate patients samples and controls. In a second phase, the company will develop a custom, 12-sample BeadChip that it will use to genotype at least 8,000 samples. Illumina will use its Sentrix BeadChips and Infinium assay for the project.


The goal is to identify potential cancer biomarkers, and to analyze chromosomal aberrations.


This is the second genotyping service agreement between the two partners in the last six months. In November, Cancer Research UK selected Illumina to provide genotyping services for colorectal cancer.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.